Skip to main content
. 2018 Dec;10(12):6677–6694. doi: 10.21037/jtd.2018.11.87

Figure 3.

Figure 3

Forest plots showing overall survival (A) and progression-free survival (B) hazard ratio analyses, with (left) and without (right) carbo + S-1. Post, posterior; carbo, carboplatin; cis, cisplatin; CrI, credible interval; doc, docetaxel; erlot, erlotinib; gem, gemcitabine; nab-tax, nab-paclitaxel; neci, necitumumab; tax, paclitaxel; vin, vinorelbine.